Department of Radiation Oncology, Chi-Mei Medical Center, Tainan, Taiwan.
Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan.
Radiat Oncol. 2021 Jan 6;16(1):6. doi: 10.1186/s13014-020-01736-8.
To assess the benefit of postoperative radiotherapy in patients with pT1-2N1M0 oral and oropharyngeal cancer by the quality of neck dissection.
In the Surveillance, Epidemiology, and End Results database, pT1-2N1M0 oral and oropharyngeal cancer patients treated by primary tumor resection and neck dissection with or without radiotherapy were included between 2004 and 2015. Univariate and multivariate analysis were used to explore the effect of adjuvant radiotherapy on 5-year overall survival (OS) and disease-specific survival (DSS) among different quality of neck dissection.
Of the 1765 patients identified, 1108 (62.8%) had oral cancer, 1141 (64.6%) were men, and 1067 (60.5%) underwent adjuvant radiotherapy. After adjusting for confounding factors, postoperative radiotherapy reduced the adjusted hazard ratio (aHR) of 5-year OS to 0.64 (95% confidence interval [CI] 0.49-0.84) in those with < 18 lymph nodes (LNs) removed, but not in those with 19-24 LNs removed (aHR 0.78; 95% CI 0.73-1.13), and in those with ≥ 25 LNs removed (aHR 0.96; 95% CI 0.75-1.24). For 5-year DSS, similar effect was observed. The adjusted hazard ratio was 0.66 (95% confidence interval, 0.45-0.97) in those with < 18 LNs. The protective effect was not seen in those with 18-24 LNs (aHR 1.07; 95% CI 0.59-1.96), and in those with ≥ 25 LNs (aHR 1.12; 95% CI 0.81-1.56). Sensitivity testing also showed a robust protective effect of postoperative radiotherapy in patients with < 18 LNs removed.
Radiotherapy was associated with improved survival in pT1-2N1M0 oral and oropharyngeal cancer patients without adequate neck dissection.
本研究旨在通过颈部解剖质量评估 pT1-2N1M0 口腔和口咽癌患者术后放疗的获益。
本研究纳入了 2004 年至 2015 年间在监测、流行病学和最终结果数据库中接受原发肿瘤切除术和颈淋巴结清扫术且未接受放疗的 pT1-2N1M0 口腔和口咽癌患者。采用单因素和多因素分析探讨不同质量的颈部解剖对辅助放疗后 5 年总生存率(OS)和疾病特异性生存率(DSS)的影响。
本研究共纳入 1765 例患者,其中 1108 例(62.8%)为口腔癌,1141 例(64.6%)为男性,1067 例(60.5%)接受了辅助放疗。调整混杂因素后,对于淋巴结清除数<18 枚的患者,术后放疗可降低 5 年 OS 的调整后风险比(aHR)至 0.64(95%置信区间[CI]0.49-0.84),但对于淋巴结清除数为 19-24 枚的患者(aHR 0.78;95% CI 0.73-1.13)和淋巴结清除数≥25 枚的患者(aHR 0.96;95% CI 0.75-1.24),这种作用不明显。对于 5 年 DSS,也观察到类似的效果。对于淋巴结清除数<18 枚的患者,调整后危险比为 0.66(95%置信区间,0.45-0.97)。对于淋巴结清除数为 18-24 枚的患者(aHR 1.07;95% CI 0.59-1.96)和淋巴结清除数≥25 枚的患者(aHR 1.12;95% CI 0.81-1.56),这种保护作用不明显。敏感性测试也表明,对于淋巴结清除数<18 枚的患者,术后放疗具有明显的生存获益。
对于颈部清扫不充分的 pT1-2N1M0 口腔和口咽癌患者,放疗与生存改善相关。